UT Health Science Center-San Antonio: Oral Pill Improves Care of Patients With Bone Marrow Cancer - Study
June 08, 2022
June 08, 2022
SAN ANTONIO, Texas, June 8 (TNSres) -- The University of Texas Health Science Center at San Antonio issued the following news release:
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 . . .
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 . . .